Payment overview · 2025
General Payments
$115.19
4 reported records · 4 companies
Healthcare provider profile · identity verified
Mohammad Ibrahim, D.O
Allopathic & Osteopathic Physicians|Family Medicine · MONTGOMERY, AL · NPI 1295081198
Verified facts
What the public records show
CMS Open Payments records show Mohammad Ibrahim, D.O received $115.19 in general payments during 2025 across 4 reported records.
INTUITIVE SURGICAL, INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $44.93 | 39.0% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $31.20 | 27.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.64 | 20.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.42 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.19 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $44.93 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 119 |
| Losartan Potassium | Losartan Potassium | 262 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 89 |
| Meloxicam | Meloxicam | 217 | 72 |
| Furosemide | Furosemide | 201 | 69 |
| Metformin Hcl | Metformin Hcl | 188 | 63 |
| Prednisone | Prednisone | 171 | 127 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 51 |
| Lisinopril | Lisinopril | 156 | 54 |
| Potassium Chloride | Potassium Chloride | 151 | 62 |
| Carvedilol | Carvedilol | 139 | 58 |
| Trazodone Hcl | Trazodone Hcl | 125 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 42 |
| Omeprazole | Omeprazole | 115 | 45 |
| Glipizide | Glipizide | 114 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 41 |
| Eliquis | Apixaban | 107 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 37 |
| Azithromycin | Azithromycin | 90 | 77 |
| Gabapentin | Gabapentin | 89 | 23 |
| Januvia | Sitagliptin Phosphate | 89 | 17 |
| Alprazolam | Alprazolam | 84 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 35 |
| Montelukast Sodium | Montelukast Sodium | 78 | 25 |
| Buspirone Hcl | Buspirone Hcl | 76 | 26 |
| Allopurinol | Allopurinol | 75 | 21 |
| Famotidine | Famotidine | 74 | 31 |
| Clonidine Hcl | Clonidine Hcl | 70 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 28 |
| Atenolol | Atenolol | 69 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 14 |
| Sertraline Hcl | Sertraline Hcl | 55 | 18 |
| Levofloxacin | Levofloxacin | 54 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 33 |
| Ozempic | Semaglutide | 52 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 29 |
| Meclizine Hcl | Meclizine Hcl | 46 | 21 |
| Memantine Hcl | Memantine Hcl | 45 | 17 |
| Simvastatin | Simvastatin | 45 | 16 |
| Cefdinir | Cefdinir | 44 | 42 |
| Donepezil Hcl | Donepezil Hcl | 44 | 14 |
| Mounjaro | Tirzepatide | 43 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 38 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Fluconazole | Fluconazole | 35 | 20 |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 11 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 30 |
| Methylprednisolone | Methylprednisolone | 31 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 29 |
| Levetiracetam | Levetiracetam | 30 | 14 |
| Spironolactone | Spironolactone | 29 | 12 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Ramipril | Ramipril | 28 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | 12 |
| Megestrol Acetate | Megestrol Acetate | 27 | 13 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | 12 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Corlanor | Ivabradine Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Klor-Con M15 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.19 · 4 records | INTUITIVE SURGICAL, INC. | AKEEGA, Da Vinci Surgical System, ERLEADA, OTEZLA, Ozempic, REPATHA, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error